Aurobindo Pharma Limited has informed the Exchange regarding a press release dated Jun 04, 2026, titled "Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma has received final approval from the US FDA to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg strengths. Tofacitinib is a generic equivalent of Pfizer's Xeljanz, commonly prescribed for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. This final approval (as opposed to tentative) allows the company to immediately launch the product in the highly lucrative US generic market. The approval strengthens Aurobindo's growing portfolio of oral solid generic products targeting the US. No specific revenue guidance or launch timeline has been disclosed in this announcement.
This is a positive development for shareholders as it adds a new product to Aurobindo's US generics pipeline and opens up an additional revenue stream, though the size of the opportunity will depend on competition and pricing once launched.